| 0.357 0.016 (4.69%) | 06-09 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.5 | 1-year : | 0.58 |
| Resists | First : | 0.42 | Second : | 0.5 |
| Pivot price | 0.34 |
|||
| Supports | First : | 0.29 | Second : | 0.2 |
| MAs | MA(5) : | 0.35  |
MA(20) : | 0.34 |
| MA(100) : | 0.59 |
MA(250) : | 1.5 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 62.5 |
D(3) : | 64.2 |
| RSI | RSI(14): 46.2 |
|||
| 52-week | High : | 4.73 | Low : | 0.2 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ALBT ] has closed below upper band by 41.0%. Bollinger Bands are 79% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 49 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.37 - 0.37 | 0.37 - 0.37 |
| Low: | 0.33 - 0.34 | 0.34 - 0.34 |
| Close: | 0.35 - 0.36 | 0.36 - 0.36 |
Avalon GloboCare Corp., along with its affiliated entities, manages and holds commercial real estate assets across both the United States and China. The company's service portfolio encompasses medical consulting, offering diverse solutions such as conducting research studies, delivering executive education, disseminating daily online briefings for executives, providing customized expert advice, and supplying management and consulting expertise, particularly in the fields of immunotherapy and in facilitating second opinions or referrals. Key therapeutic candidates include AVA-001, an anti-CD19 CAR-T therapy, which has successfully completed its initial human clinical trial for B-cell lymphoblastic leukemia that has recurred or is resistant to treatment (R/R). Another promising candidate, AVA-011, also a CAR-T cell therapy, has advanced through preclinical laboratory evaluations and is currently in the IND-enabling process development phase to produce cGMP-grade cells. The company is additionally engaged in the development of an RNA-based FASH-CARTM cell therapy platform. Furthermore, Avalon GloboCare is developing ACTEX, its proprietary clinical-grade, tissue-specific exosome. It collaborates with the Massachusetts Institute of Technology (MIT) to identify therapeutic and diagnostic targets using QTY-code protein design technology, which includes leveraging this technology to create a hemofiltration device for treating Cytokine Storm. The firm also partners with Arbele Limited for the co-development of advanced, transposon-based CAR-T, CAR-NK, and various other multi-target immune effector cell therapies. A strategic alliance with the University of Natural Resources and Life Sciences in Vienna, Austria, aims to develop an S-layer vaccine against SARS-CoV-2 (the virus responsible for COVID-19), designed for intranasal or oral delivery. Beyond these initiatives, the company is progressing with Avalon Cell and Avalon Rehab, and actively advocates for standardization within the exosome industry. Its corporate headquarters are situated in Freehold, New Jersey.
Tue, 09 Jun 2026
Avalon GloboCare (NASDAQ: ALBT) investors approve reverse split and warrants - Stock Titan
Thu, 04 Jun 2026
Avalon GloboCare Arranges Two $250,000 Notes for $400,000 Proceeds; Adds 18-Month ROFR on Equity Lines - TradingView
Thu, 04 Jun 2026
Avalon Globocare (ALBT) takes on new notes and appoints CFO under Brio deal - Stock Titan
Thu, 04 Jun 2026
Avalon GloboCare Appoints Sam Knipper CFO to Support AI Growth Strategy - citybiz
Thu, 04 Jun 2026
Press Release: Avalon GloboCare Appoints Seasoned AI and Finance Executive as Chief Financial Officer - Moomoo
Thu, 04 Jun 2026
New CFO with $40M AI financing experience joins Avalon GloboCare - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Real Estate
|
|
|
Industry:
Real Estate - Services
|
|
| Shares Out | 12 (M) |
| Shares Float | 11 (M) |
| Held by Insiders | 7.1 (%) |
| Held by Institutions | 4.5 (%) |
| Shares Short | 307 (K) |
| Shares Short P.Month | 927 (K) |
| EPS | -4.6 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -1.81 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -39.7 % |
| Return on Equity (ttm) | -501.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.66 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -6 (M) |
| Levered Free Cash Flow | -2 (M) |
| PE Ratio | -0.08 |
| PEG Ratio | 0 |
| Price to Book value | -0.2 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.7 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|